BioNTech (BNTX)
(Real Time Quote from BATS)
$104.19 USD
+0.24 (0.23%)
Updated Nov 4, 2025 10:22 AM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BNTX 104.19 +0.24(0.23%)
Will BNTX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for BNTX based on the 1-3 month trading system that more than doubles the S&P 500.

        
Zacks News for BNTX
BioNTech SE Sponsored ADR (BNTX) Is Up 4.81% in One Week: What You Should Know
Has BioNTech (BNTX) Outpaced Other Medical Stocks This Year?
BNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BNTX
BioNTech SE: Strong COVID-19 Vaccine Revenues and Pipeline Diversification Drive Buy Rating
BNTX forms 50 Day Moving Average Support on November 3
Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), BioNTech SE (BNTX) and Inspire Medical Systems (INSP)
BioNTech price target raised to $134 from $130 at BofA
BioNTech price target raised by $4 at BofA, here's why